Skip to content

Association Between Disease Severity and Clinical, Histopathological, and Eosinophilic Markers in Patients With Bullous Pemphigoid (BP-EPIC)

Correlation of Disease Severity With Histopathological Features, Serum IgE Levels, Eosinophil Count, and Tissue Expression of Eosinophilic Cationic Protein and Periostin in Patients With Bullous Pemphigoid

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07649486
Acronym
BP-EPIC
Enrollment
50
Registered
2026-06-16
Start date
2026-05-04
Completion date
2027-04-25
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bullous Pemphigoid (BP)

Keywords

bullous pemphigoid (BP), Periostin, Eosinophilic Catyonic Protein, BPDAI, IgE, Eosinophilia, Autoimmune Blistering Disease

Brief summary

Bullous pemphigoid is an autoimmune subepidermal blistering disease characterized by eosinophilic inflammation and variable disease severity. This retrospective observational study aims to evaluate the relationship between disease severity and histopathological features, serum IgE levels, peripheral eosinophil counts, and the expression of eosinophilic cationic protein (ECP) and periostin in skin biopsy specimens of patients with bullous pemphigoid. Immunohistochemical staining for ECP and periostin will be assessed semi-quantitatively and correlated with clinical and laboratory parameters, including BPDAI scores, eosinophil counts, serum IgE levels, hospitalization history, and disease relapse. The study seeks to identify potential tissue biomarkers associated with disease activity and severity in bullous pemphigoid.

Detailed description

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease and is characterized by autoantibodies directed against hemidesmosomal proteins. Eosinophils and eosinophil-associated mediators are believed to play a central role in disease pathogenesis. Periostin and eosinophilic cationic protein (ECP) have been implicated in eosinophilic inflammation; however, their relationship with clinical disease severity in BP remains incompletely understood. This single-center retrospective observational study will include patients diagnosed with bullous pemphigoid at the University of Health Sciences, Istanbul Training and Research Hospital. Clinical, laboratory, and histopathological data will be collected from medical records. The study will evaluate demographic characteristics, disease severity measured by BPDAI, serum IgE levels, peripheral eosinophil counts, hospitalization history, relapse frequency, and other clinicopathological parameters. Archived skin biopsy specimens will undergo immunohistochemical staining for periostin and ECP. Staining intensity will be assessed using semi-quantitative scoring methods and correlated with clinical and laboratory findings. The primary objective is to determine whether periostin and ECP expression levels are associated with disease severity. Secondary objectives include evaluating correlations between tissue biomarker expression and serum IgE levels, eosinophil counts, hospitalization, and disease recurrence.

Interventions

None listed

Sponsors

Istanbul Training and Research Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years. * Diagnosis of bullous pemphigoid confirmed by compatible clinical, histopathological, and/or direct immunofluorescence findings. * Availability of archived skin biopsy specimens suitable for immunohistochemical evaluation of periostin and eosinophilic cationic protein (ECP). * Availability of clinical and laboratory data, including BPDAI score, serum IgE level, and peripheral eosinophil count.

Exclusion criteria

* Age \<18 years. * Diagnosis other than bullous pemphigoid. * Inadequate or unavailable biopsy specimens for immunohistochemical analysis. * Missing clinical, histopathological, or laboratory data required for study analyses.

Design outcomes

Primary

MeasureTime frameDescription
Correlation Between BPDAI Score and Periostin Immunohistochemical ExpressionBaseline (retrospective assessment of existing clinical and histopathological data)Correlation between BPDAI disease activity score and periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens from patients with bullous pemphigoid.

Secondary

MeasureTime frameDescription
Correlation Between Periostin Immunohistochemical Expression and Serum Total IgE LevelsBaseline (retrospective assessment of existing clinical, laboratory, and histopathological dataCorrelation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and serum total IgE levels (IU/mL) in patients with bullous pemphigoid.
Correlation Between Eosinophilic Cationic Protein Immunohistochemical Expression and Peripheral Blood Eosinophil CountBaseline (retrospective assessment of existing clinical, laboratory, and histopathological data)Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and peripheral blood eosinophil count (cells/µL) in patients with bullous pemphigoid.
Correlation Between Periostin Expression and Disease Relapse FrequencyBaseline (retrospective assessment of existing clinical and histopathological dataCorrelation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and disease relapse frequency (number of relapses) in patients with bullous pemphigoid.
Correlation Between Periostin Immunohistochemical Expression and Hospitalization HistoryBaseline (retrospective assessment of existing clinical and histopathological data)Correlation between periostin immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and hospitalization history (yes/no) in patients with bullous pemphigoid.
Correlation Between Eosinophilic Cationic Protein Expression and Disease Relapse FrequencyBaseline (retrospective assessment of existing clinical and histopathological data)Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and disease relapse frequency (number of relapses) in patients with bullous pemphigoid.
Correlation Between Eosinophilic Cationic Protein Immunohistochemical Expression and Hospitalization HistoryBaseline (retrospective assessment of existing clinical and histopathological data)Correlation between eosinophilic cationic protein (ECP) immunohistochemical expression measured using a semiquantitative 0-3 staining score in skin biopsy specimens and hospitalization history (yes/no) in patients with bullous pemphigoid.
Correlation Between BPDAI Score and Eosinophilic Cationic Protein ExpressionBaseline (retrospective assessment of existing clinical, laboratory, and histopathological data)Correlation between BPDAI disease activity score and tissue eosinophilic cationic protein (ECP) expression assessed by immunohistochemistry using a semiquantitative 0-3 staining score in skin biopsy specimens from patients with bullous pemphigoid.

Countries

Turkey (Türkiye)

Contacts

STUDY_CHAIRAyse Esra Koku Aksu, Prof.Dr.

University of Health Sciences, Istanbul Training and Research Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026